Redmile Group, LLC Profound Medical Corp. Transaction History

Redmile Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$10.38 - $15.2 $8.17 Million - $12 Million	-787,346 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$16.0 - $20.59 $933,248 - $1.2 Million	-58,328 Reduced 6.9%	787,346 $12.9 Million
Q1 2021 May 17, 2021	BUY	$19.16 - $28.09 $392,339 - $575,198	20,477 Added 2.48%	845,674 $17 Million
Q4 2020 Feb 16, 2021	BUY	$16.4 - $22.9 $3,230 - $4,511	197 Added 0.02%	825,197 $17 Million
Q3 2020 Nov 16, 2020	BUY	$14.05 - $18.13 $5.97 Million - $7.71 Million	425,000 Added 106.25%	825,000 $14.6 Million
Q1 2020 May 15, 2020	BUY	$6.88 - $19.7 $2.75 Million - $7.88 Million	400,000 New	400,000 $3.9 Million

8.93M

1.2K

Ticker PROF
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,851,300
Market Cap $167M
Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.